Pregled bibliografske jedinice broj: 734160
BPC 157 prevents development of MCT-induced pulmonary hypertension and cor pulmonale in rats
BPC 157 prevents development of MCT-induced pulmonary hypertension and cor pulmonale in rats // Cardiologia Croatica
Opatija, Hrvatska, 2014. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 734160 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
BPC 157 prevents development of MCT-induced pulmonary hypertension and cor pulmonale in rats
Autori
Sikiric, Predrag ; Udovicic, Mario ; Barisic, Ivan ; Balenović, Diana ; Uzun, Sandra ; Strinić, Dean ; Lovrić Benčić, Martina ; Seiwerth, Sven
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Cardiologia Croatica
/ - , 2014
Skup
22nd Annual Meeting of the Alpe Adria. Association of Cardiology
Mjesto i datum
Opatija, Hrvatska, 30.08.2014. - 03.09.2014
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
pentadecapeptide BPC 157; monocrotaline; cor pulmonale; pulmonary hypertension; rats
Sažetak
Pentadecapeptide BPC 157 antagonises the incidence of a series of gastrointestinal lesions, it has a positive impact on the healing processes of various wounds, a proven angiogenic effect, protective effect on endothelium and it modulates synthesis of NO. BPC 157 furthermore reduces the duration of arrhythmias induced by ischemic-reperfusional injury in the isolated pig heart, and it also has an antihypertensive effect in the model of L-NAME-induced hypertension. Monocrotaline (MCT) is a pyrrolizidine alkaloid, which given subcutaneously in the rat model of pulmonary hypertension on the day 1 (80 mg/kg body weight), selectively injures the vascular endothelium of the lung and induces pulmonary vasculitis, induces muscularization and hypertrophy of themedia in pulmonary arteries, that lead to an increased vascular resistance and increased pulmonary arterial pressure. MCT-induced pulmonary hypertension is associated with the development of the compensated RV hypertrophy, which progresses to the failure within weeks. In this study, when administered ntraperitoneally from Days 1-29, BPC 157 inhibited the development of muscularization and hypertrophy of the media in pulmonary arteries, it prevented pulmonary hypertension and the right heart hypertrophy and failure. A corresponding efficacy profile was also noted for long-term peroral administration of BPC 157 in drinking water from Days 1-29. Moreover, the death rate significantly decreased in those animals treated with BPC 157. We conclude that BPC 157 prevents development of MCT-induced pulmonary hypertension and cor pulmonale in rats.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Ivan Barišić
(autor)
Predrag Sikirić
(autor)
Sven Seiwerth
(autor)
Martina Lovrić Benčić
(autor)